Skip to content
Menu

SELLAS Life Sciences Group, Inc. SLS

Full chart Compare
Set alert

Price alert · SLS

All alert types
13.66 USD -1.20 (-8.08%)

Regular-session close

14.21 +0.55 +4.03%

After hours · Nov 20, 7:58 PM ET

13.39 Day range 15.19
1.39 52-week range 19.15
YTD
+262.33%
1 year
+835.62%

5D +5.38 (+64.98%)

101520MonTueWedThuFri13.66
Market cap
2.78B
EPS (ttm)
-0.20
Shares out
203.86M
Forward P/E
-55.76
YTD return
+262.33%
1-year return
+835.62%
50-day average
11.11
200-day average
9.00
Enterprise value
2.90B
Price / book
21.08
Volume
15.48M
Avg volume
9.64M
Open
14.97
Previous close
14.86
Day's range
13.39 – 15.19
52-week range
1.39 – 19.15
Beta
2.70
Analysts
Strong Buy
Price target
37.50 (+174.5%)
Earnings date
Mar 25, 2027

Key statistics

Free cash flow
-14.92M
Total cash
134.71M
Total debt
599.00K
Return on equity
-40.31%
Short % of float
28.18%

Fundamental scorecard

4 of 25 checks passed on SLS’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
SLS Revenue — quarterly 0
SLS Net income — quarterly -10.09M
SLS EPS — quarterly -0.05

Earnings

SLS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 25, 2027Dec 30, 2026-0.05———
Nov 12, 2026Sep 30, 2026-0.05-0.050.000.00%
Aug 11, 2026Jun 30, 2026-0.045-0.05-0.01-11.11%
May 12, 2026Mar 31, 2026-0.06-0.05+0.01+16.67%
Mar 19, 2026Dec 31, 2025-0.06333-0.05+0.01+21.05%
Nov 12, 2025Sep 30, 2025-0.06333-0.060.00+5.26%

Upgrades / downgrades

SLS analyst upgrades and downgrades
DateFirmActionFromTo
Mar 12, 2026Maxim GroupmainBuyBuy
Jul 16, 2025Maxim GroupmainBuyBuy
Nov 22, 2023Cantor FitzgeraldreitOverweightOverweight
Sep 7, 2023Cantor FitzgeraldreitOverweightOverweight
Nov 15, 2022Alliance Global Partnersmain—Buy
Jun 28, 2022Cantor Fitzgeraldmain—Overweight

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on SLS — it syncs with the Stock Master app.

Insider holders

SLS insider holders
InsiderRelationLatest transactionDateShares held
BURNS JOHN THOMASChief Financial OfficerStock Award(Grant)Jan 6, 2026554,327
CICIC DRAGANOfficerStock Award(Grant)Jan 6, 2026557,805
KALIN KATHERINE BACHDirectorStock Award(Grant)Jan 6, 2026154,400
SCHEINBERG DAVID ADirectorStock Award(Grant)Jan 6, 202673,082
STERGIOU ANGELOS MChief Executive OfficerStock Award(Grant)Jun 15, 20261,759,180
VAN NOSTRAND ROBERT LDirectorStock Award(Grant)Jan 6, 202682,900

Institution ownership

SLS institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.94%16,181,634221.04MSep 29, 2026
State Street Corporation5.09%10,373,074141.70MSep 29, 2026
Vanguard Capital Management LLC4.39%8,942,647122.16MSep 29, 2026
Geode Capital Management, LLC2.54%5,171,81970.65MSep 29, 2026
Susquehanna International Group, LLP1.29%2,638,46636.04MSep 29, 2026
Vanguard Portfolio Management LLC1.13%2,297,58131.38MSep 29, 2026

Fund ownership

SLS fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.90%5,906,92280.69MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.78%5,665,91277.40MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.56%5,214,54571.23MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.05%2,134,83729.16MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund1.01%2,067,01928.24MAug 30, 2026
iShares Trust-iShares Russell 2000 Growth ETF0.92%1,880,06925.68MSep 29, 2026